Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Present and future therapy for hepatitis C virus.

Markus Cornberg1, Katja Deterding, Michael P Manns

  • 1German Competence Network for Viral Hepatitis (Kompetenznetz Hepatitis), Medizinische Hochschule Hannover, Department of Gastroenterology, Hepatology, and Endocrinology, Carl-Neuberg Str. 1, D-30625 Hannover, Germany. cornberg.markus@mh-hannover.de

Expert Review of Anti-Infective Therapy
|December 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Particularly strong immune response to influenza vaccination in patients with decompensated liver cirrhosis linked to systemic inflammation.

Frontiers in immunology·2026
Same author

Resolved HBV Infection Is Not Associated With Liver-Related Outcomes in Survival Analysis of Caucasians After HCV Cure.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

CD16<sup>+</sup> γδ T cells mediate antibody-dependent cellular cytotoxicity and associate with viral control in chronic hepatitis B virus infection.

Gut·2026
Same author

144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial.

Journal of hepatology·2026
Same author

Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B - follow-up from the RETRACT-B cohort.

Journal of hepatology·2026
Same journal

<i>Pneumocystis</i> pneumonia in non-HIV immunocompromised patients in 2026: evolving therapeutic standards.

Expert review of anti-infective therapy·2026
Same journal

Asymptomatic is not silent: proposal of HTLV-1-associated multiple inflammatory disease as an early neuroinflammatory state.

Expert review of anti-infective therapy·2026
Same journal

The endocarditis team: a review.

Expert review of anti-infective therapy·2026
Same journal

Synergistic antifungal effects and potential mode of action of crisaborole combined with azoles against drug-resistant <i>Candida albicans</i>.

Expert review of anti-infective therapy·2026
Same journal

Anti-infective therapy and novel treatment options for coccidioidomycosis.

Expert review of anti-infective therapy·2026
Same journal

Intensivists' practices and perceptions regarding β-lactam prescribing and monitoring in intensive care units: a cross-sectional survey.

Expert review of anti-infective therapy·2026
See all related articles

Hepatitis C virus (HCV) treatment has advanced significantly. Current therapies can cure many chronic HCV infections, but improved treatments and new drugs are needed for future advancements.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection presents a significant global health challenge.
  • Recent advancements in antiviral therapies have transformed HCV treatment paradigms.
  • Understanding treatment evolution is crucial for managing HCV infection.

Purpose of the Study:

  • To review current and future strategies for treating hepatitis C virus (HCV) infection.
  • To discuss the prevention of HCV infection.
  • To outline management of HCV post-liver transplantation.

Main Methods:

  • Literature review of recent advancements in HCV treatment.
  • Analysis of current standard therapies including interferon-alpha and ribavirin.
  • Exploration of emerging antiviral drugs and treatment concepts.

Related Experiment Videos

Main Results:

  • Early treatment of acute HCV infection with interferon-alpha can prevent chronicity.
  • Pegylated interferon-alpha and ribavirin can cure a significant proportion of chronic HCV patients.
  • Further improvements in treatment regimens and novel drug development are essential.

Conclusions:

  • Current therapies offer high cure rates for HCV infection.
  • Future research should focus on developing more effective and accessible treatments.
  • Comprehensive management strategies, including prevention and post-transplant care, are vital for controlling HCV.